Pharmaceutical industry response to the crisis in Ukraine
Share
2 March 2022 – As the situation in Ukraine continues to cause unimaginable suffering, our thoughts are with the people in Ukraine. Overcoming the challenges that this unprecedented humanitarian crisis poses for patients is our main concern. We are supporting the efforts of our sister regional organization – EFPIA – to ensure vital medicines reach the people who need them most and the health needs of the many thousands of people already displaced by the crisis are met.
Pharmaceutical industry response to the war in Ukraine can be found here:
https://www.efpia.eu/news-events/the-efpia-view/efpia-news/pharmaceutical-industry-response-to-the-war-in-ukraine (updated regularly)
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
Related news and resources
The innovation development and access pathway: A holistic approach to accelerating access to innovative medicines and vaccines
IFPMA introduces the “Innovation Development and Access Pathway” (IDAP), a framework designed to build a shared understanding of the end-to-end pathway of how medicines and vaccines move from discovery to delivery at the point of care. The paper maps the four critical pillars of this journey: R&D and the innovation ecosystem; regulatory processes and life cycle management; listing, procurement and reimbursement; and health service delivery. It identifies systemic challenges, and proposes collaborative solutions to overcome them, and shows that improving access requires coordinated action across stakeholders, with governments playing a central role in enabling timely and equitable access to innovation.
Read more
The role of assessment reports in enabling regulatory reliance – perspectives from the pharmaceutical industry
Reliance in decision-making offers a pathway for national regulatory authorities (NRAs) to consider evaluations conducted by other NRAs while maintaining accountability for their decisions. By avoiding duplicative reviews and optimizing resource allocation, the use of regulatory reliance can lead to faster patient access to safe, effective, and high-quality medical products in a timely manner. A...
Read more
Best practices for unilateral reliance for initial marketing authorization and post-approval changes
Regulatory reliance has emerged as a key strategy for strengthening regulatory systems by optimizing resources, reducing duplication, and accelerating access to high-quality medicines. By leveraging the expertise and prior decisions of trusted national regulatory authorities (NRAs), reliance allows NRAs to focus their efforts on critical public health priorities while maintaining sovereignty over final regulatory decisions....
Read more